MDGED
Medigene AG, a biotechnology company, focuses on the discovery and development of T-cell therapies for the treatment of cancer. The company's end-to-end platform enables the development of T cell receptor engineered T cell (TCR-T) therapies for multiple tumor indications. Its pipeline includes MDG1015, a TCR-T therapy product to treat multiple solid tumor indications; MDG10xx to treat multiple so… Read more
Market Cap & Net Worth: MDGED (MDGED)
MDGED (PINK:MDGED) has a market capitalization of $24.49K ($24.49K) as of March 19, 2026. Listed on the PINK stock exchange, this USA-based company holds position #43509 globally and #13916 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying MDGED's stock price $2.59 by its total outstanding shares 9456 (9.46K).
MDGED Market Cap History: 2015 to 2024
MDGED's market capitalization history from 2015 to 2024. Data shows change from $164.95K to $24.49K (-15.87% CAGR).
MDGED Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how MDGED's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.00x
MDGED's market cap is 0.00 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $78.12K | $8.00 Million | -$28.88 Million | 0.01x | N/A |
| 2021 | $54.34K | $10.46 Million | -$9.98 Million | 0.01x | N/A |
| 2022 | $37.45K | $31.25 Million | -$8.33 Million | 0.00x | N/A |
| 2023 | $26.13K | $6.03 Million | -$16.18 Million | 0.00x | N/A |
Competitor Companies of MDGED by Market Capitalization
Companies near MDGED in the global market cap rankings as of March 19, 2026.
Key companies related to MDGED by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
MDGED Historical Marketcap From 2015 to 2024
Between 2015 and today, MDGED's market cap moved from $164.95K to $ 24.49K, with a yearly change of -15.87%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2024 | $24.49K | -6.26% |
| 2023 | $26.13K | -30.23% |
| 2022 | $37.45K | -31.09% |
| 2021 | $54.34K | -30.44% |
| 2020 | $78.12K | -5.58% |
| 2019 | $82.74K | -50.00% |
| 2018 | $165.47K | -38.91% |
| 2017 | $270.85K | +35.45% |
| 2016 | $199.96K | +21.22% |
| 2015 | $164.95K | -- |
End of Day Market Cap According to Different Sources
On Nov 28th, 2025 the market cap of MDGED was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $24.49K USD |
| MoneyControl | $24.49K USD |
| MarketWatch | $24.49K USD |
| marketcap.company | $24.49K USD |
| Reuters | $24.49K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.